Parsippany, New Jersey. Edenbridge Pharmaceuticals, LLC announces that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for Loperamide Hydrochloride Capsules USP, 2 mg, a generic version of Imodium®* Capsules, 2mg. Loperamide Hydrochloride Capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea in patients 2 years of age and older and of chronic diarrhea in adults associated with inflammatory bowel disease. For more information please contact the Company directly at info@dexcelpharmausa.com.
Loperamide Hydrochloride Capsules, USP Approval
Specialty Products
To learn more about our specialty products, vigabatrin and Yargesa®, and how you may be able to save, please visit the Products page or navigate to a product-specific page.
Specialty Products
To learn more about our specialty products, vigabatrin and Yargesa®, and how you may be able to save, please visit the Products page or navigate to a product-specific page.